KOSDAQBiotech & Pharma383930

DT&CRO

₩1,994▲ 0.05%2026-11-18 close
Market Cap
₩25.5B
Turnover
₩84,621,300
Volume
40K
Shares out.
12.8M
PER
—
PBR
3.8×
EPS
-₩1,208
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Q3 2026 operating profit turns positive; leverage remains the key variable

DT&CRO narrowed its operating loss in 2025 and returned to a quarterly operating profit in Q3 2026, but net losses attributable to controlling shareholders have continued for three straight quarters and the debt ratio stood at 260.2% at end-2025.

  1. 1

    Revenue rose 32.7% to KRW 47.7 billion in 2025, and the operating loss narrowed to KRW 5.74 billion from KRW 11.3 billion in 2024.

  2. 2

    Operating profit in Q3 2026 was KRW 433 million, a swing to profit from a year earlier, while net loss attributable to controlling shareholders was KRW 315 million in the same quarter.

  3. 3

    Net loss attributable to controlling shareholders totaled KRW 15.5 billion over the last four quarters, from Q4 2025 through Q3 2026.

  4. 4

    The debt ratio rose from 39.3% in 2022 to 260.2% in 2025, and total liabilities of KRW 65.3 billion at end-2025 exceeded total equity of KRW 25.1 billion.

  5. 5

    The company says its PK/PD center and other investments completed a full-service CRO structure, and it has set 2026 as the year growth should accelerate.

02

Business structure

DT&CRO is a clinical trial service provider founded in 2017 that offers clinical and non-clinical testing for pharmaceuticals, as well as health functional foods and cosmetics. It listed on KOSDAQ in November 2022 and is headquartered in Yongin, Gyeonggi Province.

Its services span non-clinical work (efficacy evaluation, GLP toxicity testing, safety testing), clinical trials from Phase 1 to Phase 4, bioanalysis, central lab services, and regulatory and development strategy consulting.

According to a corporate monitoring service, safety testing accounted for nearly half of revenue in the first half of 2026.

The PK/PD center, opened in March 2025, built ADME testing infrastructure that allows the company to perform pharmacokinetic and pharmacodynamic analysis in-house, work that was previously outsourced to overseas CROs.

On this basis the company promotes a full-service CRO structure that links non-clinical work, clinical trials and regulatory filings. In the generic-improvement segment, the company said in October 2026 it had completed 54 Phase 1 clinical trials and 26 toxicity studies for combination drugs.

Its customers are mainly domestic pharmaceutical and biotech firms, and the company says aesthetics-related orders are rising. It said in June 2026 that it would attend the BIO USA 2026 Korea Pavilion and pursue partnering meetings with overseas companies.

Competitively, it overlaps with domestic and overseas CROs that offer both non-clinical and clinical services, and the company emphasizes its integrated CRO model as its differentiator.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩12.6B-₩900M−7.2%
2025Q4₩15B₩600M4.1%
2026Q1₩10.1B-₩3.6B−35.4%
2026Q2₩11.3B-₩6.6B−58.1%
2026Q3₩14.5B₩400M3.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩44B₩5.3B₩5.3B12.0%11.3%39.3%
2023₩26.6B-₩12.1B-₩16.6B−45.6%−52.5%88.9%
2024₩36B-₩11.3B-₩2B−31.4%−7.0%182.8%
2025₩47.7B-₩5.7B-₩2.8B−12.0%−11.1%260.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual results show revenue growth and a narrowing loss. Revenue fell from KRW 44 billion in 2022 to KRW 26.6 billion in 2023, a 39.6% decline, then recovered to KRW 36 billion in 2024 (up 35.3%) and KRW 47.7 billion in 2025 (up 32.7%). The 2025 figure was the largest of the 2022 to 2025 period.

The company attributed the 2025 revenue increase to expanded orders. Operating profit of KRW 5.29 billion in 2022 turned into an operating loss of KRW 12.1 billion in 2023, followed by an operating loss of KRW 11.3 billion in 2024 and KRW 5.74 billion in 2025, so losses continued but narrowed.

The operating margin moved from 12.0% in 2022 to -45.6% in 2023, then improved to -31.4% in 2024 and -12.0% in 2025. Press coverage has linked the narrower loss to a stabilizing cost structure after large facility investments wound down.

Net profit attributable to controlling shareholders was KRW 5.26 billion in 2022, turned into a net loss of KRW 16.6 billion in 2023, narrowed to a net loss of KRW 2 billion in 2024, and widened again to a net loss of KRW 2.78 billion in 2025.

Net profit including non-controlling interests shows the same annual figures in the filed table: KRW 5.26 billion in 2022 and net losses of KRW 16.6 billion, KRW 2 billion and KRW 2.78 billion in 2023 through 2025.

Operating cash flow was KRW 5.01 billion in 2022, then negative at KRW -3.52 billion in 2023, KRW -6.4 billion in 2024 and KRW -2.26 billion in 2025.

The debt ratio rose from 39.3% in 2022 to 88.9% in 2023, 182.8% in 2024 and 260.2% in 2025, when total liabilities were KRW 65.3 billion against total equity of KRW 25.1 billion.

Quarterly revenue was KRW 12.6 billion in Q3 2025 and KRW 15 billion in Q4 2025 (up 19.4% quarter on quarter), then fell to KRW 10.1 billion in Q1 2026 (down 32.5%). It rose to KRW 11.3 billion in Q2 2026 (up 11.5%) and KRW 14.5 billion in Q3 2026 (up 28.8% quarter on quarter and 15.7% year on year).

Operating profit was KRW 621 million in Q4 2025, then the company posted operating losses of KRW 3.58 billion in Q1 2026 and KRW 6.57 billion in Q2 2026 before returning to operating profit of KRW 433 million in Q3 2026.

Net loss attributable to controlling shareholders was KRW 1.96 billion in Q3 2025, a profit of KRW 2.74 billion in Q4 2025, KRW 13.8 billion in Q1 2026, KRW 4.1 billion in Q2 2026 and KRW 315 million in Q3 2026.

The causes of the sharp Q1 2026 loss, including whether any one-off costs were involved, are items to confirm in the notes to the next annual report.

05

Industry analysis

Domestic CRO demand moves with the pharmaceutical and biotech cycle. The company said non-clinical and clinical orders increased as the domestic pharma and biotech environment recovered from the second half of 2025. Its order backlog at the end of Q3 2025 was KRW 49.6 billion, up 16% from a year earlier.

After government drug price reform proposals for off-patent medicines, the company observes that pharmaceutical firms are shifting from a generic-centric model toward R&D on new drugs and combination products.

The company expects this shift to create order opportunities for providers of integrated services spanning non-clinical through clinical work. Development of improved new drugs and combination products uses existing ingredients and accumulated safety and efficacy data, which aligns with CRO demand.

Because the customer base is weighted toward small and mid-sized pharmaceutical companies, order flow may be sensitive to the R&D budgets of those clients.

The company also sees a gap in demand from Chinese CROs as an opportunity and said it built secure, real-time data management systems at its PK/PD center in response. The US Biosecure Act has also been cited as a potentially favorable factor for domestic CROs.

In terms of competitive position, the company describes itself as closer to an integrated provider when measured by its linkage of non-clinical, clinical, analytical and regulatory services.

06

Outlook

The company describes 2026 as the year its full-service CRO structure is completed and growth should accelerate. Its 2026 plan includes establishing a bioanalysis center and hiring oncology specialists to expand into biologics and anticancer drug development.

It also plans to continue research and investment in New Approach Methodologies (NAMs).

In October 2026 the company signed a memorandum with the Korea Innovative Medicines Consortium (KIMCo Foundation) to support drug development at startups, and it is pursuing AI-based clinical research with Korea University Guro Hospital.

On October 15, 2026 it said it would complete phase 1 development of AI-based digital pathology for liver tissue by April 2027. On October 19, 2026 it announced stronger integrated services linking non-clinical work, clinical design and regulatory strategy for improved new drugs and combination products.

For its contract with the Incheon Regional Procurement Office on chemical hazard testing, the company said in an October 2026 amended filing that it expects to complete the contract amendment in November, after an advance payment of 80% of the pre-amendment contract value was made on October 1, 2025.

The next checkpoint is how much 2026 annual revenue grows from KRW 47.7 billion in 2025 and how far the operating loss narrows. Because the operating losses in Q1 and Q2 2026 were large, whether profitability continues after Q4 will determine how much the full-year loss narrows.

07

Valuation

PER
—
PBR
3.8×
ROE
-102.1%
EPS
-₩1,208
BPS
₩539
Dividend per share
₩0

Price-to-earnings cannot be calculated because net losses over the last four quarters leave no meaningful earnings base.

Price-to-book sits in a range where the stock carries a premium to net asset value, so interpretation depends on whether investors weigh asset value or growth expectations, given continued net losses attributable to controlling shareholders.

The dividend yield is effectively near zero, so comparisons based on dividend-based valuation do not apply.

The company moved from a profit in 2022 to losses in 2023, and losses have alternated between narrowing and widening through 2025, while operating profit turned positive in Q3 2026, a development that points to a direction of earnings recovery.

The variables for how the multiples are read are the duration of continued losses, how capital is raised and whether convertible bonds convert, and how quickly the order backlog converts into revenue. With a debt ratio of 260.2%, the price-to-book reading should be considered alongside the debt burden.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Revenue recovery and order growth

Revenue rose 32.7% to KRW 47.7 billion in 2025 and grew for two consecutive years from 2024 to 2025 after the 2023 low. The order backlog at the end of Q3 2025 was KRW 49.6 billion, up 16% from a year earlier, according to press reports. Q3 2026 revenue of KRW 14.5 billion was up 15.7% from the same quarter a year earlier.

Full-service infrastructure and improved-drug experience

The company positions its PK/PD center and ADME testing infrastructure as a basis for linking non-clinical work, clinical trials and regulatory filings in one place.

It highlights 54 Phase 1 trials for improved new drugs and 26 toxicity studies for combination products as experience in an area with pharmaceutical demand. Q3 2026 operating profit of KRW 433 million marked a swing to profit from a year earlier.

Expected R&D demand from drug price reform

The company's view is that drug price reform prompting pharmaceutical firms to expand R&D on new drugs and combination products creates order opportunities for it. It is broadening its demand base through agreements with the KIMCo Foundation and Korea University Guro Hospital. Phase 1 of its AI digital pathology technology is scheduled for completion by April 2027.

09

Bear factors

Renewed quarterly operating losses

Operating losses were KRW 3.58 billion in Q1 2026 and KRW 6.57 billion in Q2 2026, widening through the first half. Q3 2026 returned to operating profit of KRW 433 million, but one profitable quarter is too early to call a trend change.

Net loss attributable to controlling shareholders reached KRW 13.8 billion in Q1 2026, a large single-quarter loss.

High debt ratio

At the end of 2025, total liabilities were KRW 65.3 billion against total equity of KRW 25.1 billion, a debt ratio of 260.2%. The debt ratio climbed from 39.3% in 2022 through 182.8% in 2024. Operating cash flow was negative in each year from 2023 to 2025.

Reliance on financing and dilution risk

In February 2026 the company issued a KRW 14 billion private convertible bond and a KRW 6 billion private bond with warrants. It said it had secured a KRW 20 billion investment from Eugene Private Equity. Convertible and warrant instruments can increase the share count, so dilution should be monitored.

10

Risk factors

Financial liquidity

Total liabilities of KRW 65.3 billion exceeded total equity of KRW 25.1 billion at end-2025, and convertible and warrant bond issuance continued in February 2026. In December 2025 the company said its investment fundraising was in its final stage in response to liquidity concerns. Whether financing proceeds as planned is the key item to monitor for financial risk.

Order volatility and timing

CRO revenue moves quarter to quarter with the timing of clients' clinical and non-clinical orders. Q1 2026 revenue fell 32.5% from the prior quarter before recovering to KRW 14.5 billion in Q3. A growing order backlog does not guarantee that revenue arrives in the same quarter.

Share price volatility and exchange alerts

The Korea Exchange designated DT&CRO as an investment caution stock for one day, on November 10, 2026, citing concentrated trading in a small number of accounts. According to the filing, the share price rose 18.05% over the prior three days and the top ten accounts accounted for 46.36% of buying.

The exchange applies caution, warning and risk stages in that order, and trading can be suspended at the warning and risk stages.

11

What to watch next

  1. Late November 2026

    Completion of the contract amendment for the chemical hazard testing supply deal with the Incheon Regional Procurement Office and the revised contract value in the filing. The company expected completion in November.

  2. Early February 2027

    Preliminary 2026 full-year results. The 2025 annual results were disclosed on February 4, 2026. Revenue growth and the extent of the operating loss reduction are the next checkpoints.

  3. Late March 2027

    Deadline for filing the 2026 annual business report for a December year-end company. Operating results, operating cash flow, the debt ratio and Q4 results become confirmed filed figures.

  4. April 2027

    Target date for completing phase 1 of the AI-based liver tissue digital pathology technology. It shows progress in expanding the use of non-clinical data.

12

Overall view

DT&CRO is in the process of improving its earnings profile, with 2025 revenue of KRW 47.7 billion (up 32.7%) and a narrower operating loss. Q3 2026 operating profit of KRW 433 million marked a swing to profit, and revenue of KRW 14.5 billion rose from a year earlier.

However, net loss attributable to controlling shareholders has been negative for three consecutive quarters since Q1 2026, and the last four quarters total KRW 15.5 billion. On the balance sheet, the debt ratio is 260.2%, with total liabilities of KRW 65.3 billion exceeding total equity of KRW 25.1 billion.

In 2026 the company raised funds through convertible and warrant bonds and a KRW 20 billion investment. Bullish factors include its full-service CRO infrastructure, expected R&D demand from drug price reform, and a growing order backlog.

Bearish factors include renewed quarterly operating losses, financial burden and possible share dilution. On valuation, price-to-earnings cannot be calculated due to continued losses, and price-to-book sits at a premium to net asset value, so the pace of earnings recovery is central to interpretation.

Items to confirm are the operating results and cash flow in the 2026 annual business report, preliminary full-year results expected around February 2027, and whether phase 1 of the AI digital pathology project is completed by April 2027. This summary is for informational purposes and does not include a buy or sell opinion or a target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. news.nate.com
  3. jobkorea.co.kr
  4. news.bizwatch.co.kr
  5. saramin.co.kr
  6. v.daum.net
  7. fnnews.com
  8. pharm.edaily.co.kr
  9. press9.kr
  10. thebionews.net
  11. m.yakup.com
  12. news.nate.com
  13. fnnews.com
  14. fnnews.com
  15. newspim.com
  16. dtncro.next-v.co.kr
  17. newspim.com
  18. vegannews.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis